Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. - Natali A; Nesti L; Fabiani I; Calogero E; Di Bello V (Cardiovascular diabetology, 2017)